Tubulin Detyrosination: An Emerging Therapeutic Target in Hypertrophic Cardiomyopathy.
作者信息
Margulies Kenneth B, Prosser Benjamin L
机构信息
Department of Medicine (K.B.M.), Perelman School of Medicine, University of Pennsylvania, Philadelphia.
Department of Physiology (K.B.M., B.L.P.), Perelman School of Medicine, University of Pennsylvania, Philadelphia.
出版信息
Circ Heart Fail. 2021 Jan;14(1):e008006. doi: 10.1161/CIRCHEARTFAILURE.120.008006. Epub 2021 Jan 12.
Abstract
摘要
相似文献
1
Tubulin Detyrosination: An Emerging Therapeutic Target in Hypertrophic Cardiomyopathy.微管蛋白去酪氨酸化：肥厚型心肌病中一个新出现的治疗靶点。
Circ Heart Fail. 2021 Jan;14(1):e008006. doi: 10.1161/CIRCHEARTFAILURE.120.008006. Epub 2021 Jan 12.
2
Progression from hypertrophic obstructive cardiomyopathy to congestive cardiomyopathy in a child.一名儿童肥厚型梗阻性心肌病进展为充血性心肌病。
Am Heart J. 1982 Jul;104(1):155-6. doi: 10.1016/0002-8703(82)90654-8.
3
Proteomic and Functional Studies Reveal Detyrosinated Tubulin as Treatment Target in Sarcomere Mutation-Induced Hypertrophic Cardiomyopathy.蛋白质组学和功能研究揭示去酪氨酸化微管蛋白作为致肌节突变性肥厚型心肌病的治疗靶点。
Circ Heart Fail. 2021 Jan;14(1):e007022. doi: 10.1161/CIRCHEARTFAILURE.120.007022. Epub 2021 Jan 12.
4
September 2016 at a glance: pregnancy, hypertrophic cardiomyopathy, epidemiology, medical treatment.2016年9月概览：妊娠、肥厚型心肌病、流行病学、医学治疗
Eur J Heart Fail. 2016 Sep;18(9):1091-2. doi: 10.1002/ejhf.627.
5
[Hypothyroid cardiomyopathy--an underdiagnosed cause of heart failure].[甲状腺功能减退性心肌病——心力衰竭的一个诊断不足的病因]
Tidsskr Nor Laegeforen. 1990 Jun 10;110(15):1948-51.
6
[Hypertrophic cardiomyopathy (clinical aspects, diagnosis and treatment)].[肥厚型心肌病（临床方面、诊断与治疗）]
Kardiologiia. 1990 Nov;30(11):7-13.
7
Apical hypertrophic cardiomyopathy.心尖肥厚型心肌病
South Med J. 1996 Jul;89(7):711-3. doi: 10.1097/00007611-199607000-00012.
8
Idiopathic hypertrophic subaortic stenosis (hypertrophic obstructive cardiomyopathy) changing concepts-1975.特发性肥厚性主动脉瓣下狭窄（肥厚性梗阻性心肌病）：观念的转变-1975年
Chest. 1975 Dec;68(6):814-7. doi: 10.1378/chest.68.6.814.
9
10
[Hypertrophic cardiomyopathies--present knowledge].[肥厚型心肌病——当前认知]
Med Trop (Mars). 1986 Jan-Mar;46(1):89-91.
引用本文的文献
1
Tubulin tyrosine ligase variant perturbs microtubule tyrosination, causing hypertrophy in patient-specific and CRISPR gene-edited iPSC-cardiomyocytes.微管蛋白酪氨酸连接酶变体扰乱微管酪氨酸化，在患者特异性和CRISPR基因编辑的诱导多能干细胞衍生心肌细胞中导致肥大。
JCI Insight. 2025 Aug 8;10(15). doi: 10.1172/jci.insight.187942.
2
Investigation of the Effects of Salinity Exposure on Immune Defense, Morphology, and Gene Expression in the Gills of .盐度暴露对[物种名称]鳃的免疫防御、形态学及基因表达影响的研究
Antioxidants (Basel). 2025 May 29;14(6):655. doi: 10.3390/antiox14060655.
3
Transcriptome Profiling Analysis Reveals Changes in the Antioxidant Defense System, Morphology, and Gene Expression in the Gills of Caused by Alkalinity Exposure.转录组分析揭示了碱度暴露导致的[具体生物名称未给出]鳃中抗氧化防御系统、形态和基因表达的变化。
Int J Mol Sci. 2025 May 1;26(9):4321. doi: 10.3390/ijms26094321.
4
AGBL2 promotes renal cell carcinoma cells proliferation and migration via α-tubulin detyrosination.AGBL2通过α-微管蛋白去酪氨酸化促进肾癌细胞增殖和迁移。
Heliyon. 2024 Sep 4;10(18):e37086. doi: 10.1016/j.heliyon.2024.e37086. eCollection 2024 Sep 30.
5
The microtubule cytoskeleton in cardiac mechanics and heart failure.心脏力学和心力衰竭中的微管细胞骨架。
Nat Rev Cardiol. 2022 Jun;19(6):364-378. doi: 10.1038/s41569-022-00692-y. Epub 2022 Apr 19.
6
Cardiomyocyte Microtubules: Control of Mechanics, Transport, and Remodeling.心肌细胞微管：力学、运输和重构的控制。
Annu Rev Physiol. 2022 Feb 10;84:257-283. doi: 10.1146/annurev-physiol-062421-040656. Epub 2021 Oct 6.
本文引用的文献
1
Proteomic and Functional Studies Reveal Detyrosinated Tubulin as Treatment Target in Sarcomere Mutation-Induced Hypertrophic Cardiomyopathy.蛋白质组学和功能研究揭示去酪氨酸化微管蛋白作为致肌节突变性肥厚型心肌病的治疗靶点。
Circ Heart Fail. 2021 Jan;14(1):e007022. doi: 10.1161/CIRCHEARTFAILURE.120.007022. Epub 2021 Jan 12.
2
Depletion of Vasohibin 1 Speeds Contraction and Relaxation in Failing Human Cardiomyocytes.血管抑肽 1 的耗竭可加速衰竭人心肌细胞的收缩和舒张。
Circ Res. 2020 Jul 3;127(2):e14-e27. doi: 10.1161/CIRCRESAHA.119.315947. Epub 2020 Apr 10.
3
Microtubules regulate cardiomyocyte transversal Young's modulus.微管调节心肌细胞横向杨氏模量。
Proc Natl Acad Sci U S A. 2020 Feb 11;117(6):2764-2766. doi: 10.1073/pnas.1917171117. Epub 2020 Jan 27.
4
Microtubules Increase Diastolic Stiffness in Failing Human Cardiomyocytes and Myocardium.微管增加衰竭人心肌细胞和心肌的舒张僵硬性。
Circulation. 2020 Mar 17;141(11):902-915. doi: 10.1161/CIRCULATIONAHA.119.043930. Epub 2020 Jan 16.
5
Suppression of detyrosinated microtubules improves cardiomyocyte function in human heart failure.去酪氨酸化微管的抑制可改善人心力衰竭患者的心肌细胞功能。
Nat Med. 2018 Aug;24(8):1225-1233. doi: 10.1038/s41591-018-0046-2. Epub 2018 Jun 11.
6
Detyrosinated microtubules buckle and bear load in contracting cardiomyocytes.去酪氨酸化微管在收缩心肌细胞中发生弯曲并承受负荷。
Science. 2016 Apr 22;352(6284):aaf0659. doi: 10.1126/science.aaf0659.
7
Surgery insight: Septal myectomy for obstructive hypertrophic cardiomyopathy--the Mayo Clinic experience.手术洞察：梗阻性肥厚型心肌病的室间隔心肌切除术——梅奥诊所的经验
Nat Clin Pract Cardiovasc Med. 2007 Sep;4(9):503-12. doi: 10.1038/ncpcardio0965.
8
Parthenolide induces a distinct pattern of oxidative stress in cardiac myocytes.小白菊内酯在心肌细胞中诱导出一种独特的氧化应激模式。
Free Radic Biol Med. 2007 Feb 15;42(4):474-81. doi: 10.1016/j.freeradbiomed.2006.11.012. Epub 2006 Nov 15.
Zotero 插件